ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00805506
Recruitment Status : Completed
First Posted : December 9, 2008
Last Update Posted : November 26, 2015
Sponsor:
Collaborators:
International Diabetes Center at Park Nicollet
LifeScan
Information provided by:
HealthPartners Institute

Brief Summary:
Evaluate the usefulness of continuous glucose monitoring devices in terms of their ability to identify periods throughout the day when glucose varies significantly.

Condition or disease
Diabetes

Detailed Description:
Many CGM systems use a surrogate for blood glucose--tissue glucose or interstitial glucose. Interstitial fluid (ISF) is the medium for these approaches. A physiological lag in ISF glucose relative to capillary blood glucose has been noted, probably due to relatively low blood perfusion at the sampling site. 9 This physiological lag can result in an accuracy error, manifesting as a significant bias between blood and tissue glucose, particularly during periods of rapid glucose change. This lag error might be particularly meaningful when glucose is rapidly dropping towards hypoglycemia.

Study Type : Observational
Actual Enrollment : 16 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes
Study Start Date : February 2006
Actual Primary Completion Date : April 2007
Actual Study Completion Date : April 2007

Group/Cohort
Diabetes Insulin Treated
People with type 1 or type 2 diabetes on insulin.



Primary Outcome Measures :
  1. To collect sufficient glucose data by means of continuous glucose monitoring for the purpose of detecting clinically relevant alterations in blood glucose throughout a typical or modal day. [ Time Frame: 9 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
adults with diabetes who are treated with insulin
Criteria

Inclusion Criteria:

  • adult
  • A1c >7.4 within last 4 months
  • type 1 or 2 diabetes treated with basal/bolus insulin

Exclusion Criteria:

  • under 18 years of age
  • unable to read/write english
  • allergy to adhesives
  • employee of CGM company

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00805506


Locations
United States, Minnesota
International Diabetes Center
Minneapolis, Minnesota, United States, 55416
Sponsors and Collaborators
HealthPartners Institute
International Diabetes Center at Park Nicollet
LifeScan
Investigators
Principal Investigator: Roger S Mazze, PhD International Diabetes Center at Park Nicollet
Principal Investigator: Elinor (Ellie) S Strock, APRN BC International Diabetes Center at Park Nicollet

Responsible Party: Roger S. Mazze, PhD, International Diabetes Center
ClinicalTrials.gov Identifier: NCT00805506     History of Changes
Other Study ID Numbers: 03349-05-A
First Posted: December 9, 2008    Key Record Dates
Last Update Posted: November 26, 2015
Last Verified: December 2008

Keywords provided by HealthPartners Institute:
continuous glucose monitoring accuracy

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases